WO1999000490A3 - Attenuated human immunodeficiency virus vaccine - Google Patents

Attenuated human immunodeficiency virus vaccine Download PDF

Info

Publication number
WO1999000490A3
WO1999000490A3 PCT/CA1998/000617 CA9800617W WO9900490A3 WO 1999000490 A3 WO1999000490 A3 WO 1999000490A3 CA 9800617 W CA9800617 W CA 9800617W WO 9900490 A3 WO9900490 A3 WO 9900490A3
Authority
WO
WIPO (PCT)
Prior art keywords
pbs
human immunodeficiency
immunodeficiency virus
viral
dna
Prior art date
Application number
PCT/CA1998/000617
Other languages
French (fr)
Other versions
WO1999000490A2 (en
Inventor
Mark A Wainberg
Original Assignee
Sir Mortimer B Davis Jewish Ge
Mark A Wainberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sir Mortimer B Davis Jewish Ge, Mark A Wainberg filed Critical Sir Mortimer B Davis Jewish Ge
Priority to AU80969/98A priority Critical patent/AU8096998A/en
Publication of WO1999000490A2 publication Critical patent/WO1999000490A2/en
Publication of WO1999000490A3 publication Critical patent/WO1999000490A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Reverse transcription of retroviruses is initiated from an 18 nucleotide primer binding site (PBS), located within the 5' region of viral genomic RNA, to which the host cell-derived tRNA primer is annealed and also involves viral genomic sequences outside the PBS. Significantly lower levels of viral DNA are detected in cells infected with proviral DNA clones of human immunodeficiency virus (HIV) selectively deleted in regard to a segment found immediately downstream of the PBS. This segment is involved in efficient expression of each of viral DNA, mRNA, and infectious virus. The deleted DNA clones are useful for the preparation of an HIV vaccine.
PCT/CA1998/000617 1997-06-26 1998-06-26 Attenuated human immunodeficiency virus vaccine WO1999000490A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU80969/98A AU8096998A (en) 1997-06-26 1998-06-26 Attenuated human immunodeficiency virus vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,208,946 1997-06-26
CA002208946A CA2208946A1 (en) 1997-06-26 1997-06-26 Attenuated human immunodeficiency virus vaccine

Publications (2)

Publication Number Publication Date
WO1999000490A2 WO1999000490A2 (en) 1999-01-07
WO1999000490A3 true WO1999000490A3 (en) 1999-03-18

Family

ID=4160956

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1998/000617 WO1999000490A2 (en) 1997-06-26 1998-06-26 Attenuated human immunodeficiency virus vaccine

Country Status (3)

Country Link
AU (1) AU8096998A (en)
CA (1) CA2208946A1 (en)
WO (1) WO1999000490A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012535A2 (en) * 2003-08-01 2005-02-10 Phytovation B.V. Method for producing life attenuated viruses and use of viral particles thus produced.
EP2521773A1 (en) 2010-01-04 2012-11-14 Novozymes A/S Alpha-amylases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580761A (en) * 1988-02-16 1996-12-03 Greatbatch Gen-Aid Ltd. Method of conferring resistance to immunodeficiency viral infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580761A (en) * 1988-02-16 1996-12-03 Greatbatch Gen-Aid Ltd. Method of conferring resistance to immunodeficiency viral infection

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DAS A T ET AL: "Sequence variation of the human immunodeficiency virus primer-binding site suggests the use of an alternative tRNA(Lys) molecule in reverse transcription.", JOURNAL OF GENERAL VIROLOGY, (1997 APR) 78 ( PT 4) 837-40, XP002088583 *
HUANG Y ET AL: "The role of nucleocapsid and U5 stem/A-rich loop sequences in tRNA(3Lys) genomic placement and initiation of reverse transcription in human immunodeficiency virus type 1.", JOURNAL OF VIROLOGY, (1998 MAY) 72 (5) 3907-15, XP002088589 *
LI X ET AL: "Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication.", JOURNAL OF VIROLOGY, (1994 OCT) 68 (10) 6198-206, XP002088585 *
LI X ET AL: "Human immunodeficiency virus Type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA(Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site.", JOURNAL OF VIROLOGY, (1996 AUG) 70 (8) 4996-5004, XP002088584 *
LI X ET AL: "Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1.", JOURNAL OF VIROLOGY, (1997 AUG) 71 (8) 6003-10, XP002088586 *
VAN LINT C ET AL: "Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity.", JOURNAL OF VIROLOGY, (1997 AUG) 71 (8) 6113-27, XP002088587 *
WAINBERG, M. A. ET AL: "Non-coding LTR sequences downstream of the primer binding site are required for efficient replication of the human immunodeficiency virus type 1.", JOURNAL OF MOLECULAR MEDICINE (BERLIN), (1997) VOL. 75, NO. 7, PP. B212. MEETING INFO.: XIX SYMPOSIUM OF THE INTERNATIONAL ASSOCIATION FOR COMPARATIVE RESEARCH ON LEUKEMIA AND RELATED DISEASES HEIDELBERG, GERMANY JULY 13-18, 1997, XP002088588 *

Also Published As

Publication number Publication date
WO1999000490A2 (en) 1999-01-07
CA2208946A1 (en) 1998-12-26
AU8096998A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
Böhnlein et al. Identification of a U5-specific sequence required for efficient polyadenylation within the human immunodeficiency virus long terminal repeat
EP0887427A3 (en) Amplification and detection of hiv-1 and/or hiv-2
CA2243570A1 (en) Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv
EP2336370A3 (en) Recombinant Newcastle disease virus RNA expression systems and vaccines
EP1437400A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
EP1642987A3 (en) Nucleotide sequences derived from the genomes of the retroviruses HIV-1, HIV-2 and SIV, and their application to the amplification of these viral genomes and to the in vitro diagnosis of infections resulting from these viruses
AU8499901A (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
DK605987D0 (en) Certain DNA sequences derived from a papilloma virus genome, their use for in vitro diagnostic and preparation of antigenic preparations
WO2005034992A3 (en) Hiv vaccines based on env of multiple clades of hif
Hayashi et al. Elucidation of a conserved RNA stem-loop structure in the packaging signal of human immunodeficiency virus type 1
MXPA03000061A (en) Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof.
WO2002087614A3 (en) Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen
EP0854197A3 (en) Primers for the detection of HIV-1
RU98100921A (en) HIV-1 PRIMERS
WO1999000490A3 (en) Attenuated human immunodeficiency virus vaccine
EP1035220A3 (en) Oligonucleotide primers for efficient multiplex detection of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) and methods of use thereof
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
CA2406830A1 (en) Method for mutation detection in hiv using pol sequencing
EP2128256A3 (en) Molecular clones with mutated HIV GAG/POL, SIV GAG and SIV ENV genes
WO1999057284A3 (en) Attenuated influenza viruses
Chang et al. Sequence note sequence features downstream of the primer-binding site of HIV type 1 subtype E shared by subtype G and a subset of subtype A
WO2001042299A3 (en) Hepatitis virus sentinel virus i (svi)
Blanchard et al. Future vaccines for HIV

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999505173

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase